Mehmet Burak Mutlu

Mehmet Burak Mutlu

Auto-generated profile, based on publicly available information

Mehmet Burak Mutlu

Detagen Genetic Diseases Evaluation Center, Kayseri, Türkiye

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in Clinical Genetics
Verified
Journal Article
Closed access
MMMehmet Burak Mutlu
Mehmet Burak Mutlu
TKTaner KARAKAYA
Taner KARAKAYA
HÇHamide Betül Gerik Çelebi
Hamide Betül Gerik Çelebi
FDFahrettin Duymuş
Fahrettin Duymuş
SSSerhat Seyhan
Serhat Seyhan
HGHakan Gümüş
Hakan Gümüş

30 November 2024 in International Journal of Developmental Neuroscience
Verified
Journal Article
Closed access
FKFethiye Kılıçaslan
Fethiye Kılıçaslan
ÖÖÖzlem Öz
Özlem Öz
MMMehmet Burak Mutlu
Mehmet Burak Mutlu

1 January 2025 in Pediatric Diabetes
Verified
Journal Article
Open access
ASAslıhan Sanrı
Aslıhan Sanrı
TÇTugba Kontbay Çetin
Tugba Kontbay Çetin
EAEmel Gul Acikgoz
Emel Gul Acikgoz
MMMehmet Burak Mutlu
Mehmet Burak Mutlu
OSOzlem Sezer
Ozlem Sezer
Objective: Maturity‐onset diabetes of the young (MODY) represents a genetically and clinically heterogeneous form of monogenic diabetes caused by defects in pancreatic β‐cell function. Accurate molecular diagnosis is essential for distinguishing MODY from type 1 and type 2 diabetes, enabling precision‐based management and targeted therapy. This study aimed to evaluate the genetic and clinical features of pediatric patients with MODY, to assess the prevalence of common and rare subtypes, and to report novel pathogenic variants identified in a Turkish cohort. Methods: This single‐center, retrospective cohort study evaluated 81 pediatric patients with suspected MODY followed between 2022 and 2025. Genetic analysis was performed using targeted next‐generation sequencing (NGS) panels, including HNF4A , GCK , HNF1A , PDX1 , HNF1B , NEUROD1 , INS , ABCC8 , KCNJ11 , APPL1 , and CEL . Patients were selected based on the presence of at least two clinical features suggestive of MODY, as defined by the 2022 International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines. Demographic, biochemical, and clinical data were extracted from hospital records and analyzed descriptively. Results: Genetic variants were identified in 25 of 81 patients (30.9%), including pathogenic, likely pathogenic, and variants of uncertain significance (VUS). Of these, 22 variants were classified as pathogenic or likely pathogenic, corresponding to a diagnostic yield of 27.2%. The most frequently affected gene was GCK (72.0%), followed by HNF1A (8.0%), with single cases identified in HNF1B , INS , PDX1 , CEL , and KCNJ11 . Rare MODY subtypes collectively accounted for 20.0%. Three novel GCK variants c.1055T >C, c.1229A >C, and c.185_186insA were identified. One patient with syndromic features harbored a heterozygous 17q12 microdeletion encompassing HNF1B , approximately 1.5 Mb in size, and presented with global developmental delay, intellectual disability, epilepsy, dysmorphic facial features, persistent hypomagnesemia, and a bicornuate uterus with normal renal structure. Following genetic analysis, two patients had therapy adjustments based on the identified variants. Conclusion: This study underscores the clinical and genetic heterogeneity of MODY in the pediatric population and reinforces the value of comprehensive NGS panels for accurate diagnosis, even in patients who do not fully meet classical MODY criteria. The identification of novel GCK variants and the detection of rare subtypes further expand the mutational and phenotypic spectrum of pediatric monogenic diabetes. These findings highlight the importance of incorporating population‐specific genomic data into clinical practice and of periodically re‐evaluating gene–disease associations as new molecular and functional evidence emerges. Ultimately, the integration of molecular diagnostics into routine pediatric diabetes care will enhance diagnostic yield, optimize management, and improve long‐term outcomes for affected families.

24 April 2017 in Congenital Anomalies
Verified
Journal Article
Open access
PDF file
ACArda Cetinkaya
Arda Cetinkaya
AKAli Karaman
Ali Karaman
MMMehmet Burak Mutlu
Mehmet Burak Mutlu
TYTaner Yavuz
Taner Yavuz

23 October 2025 in Molecular Syndromology
Verified
Journal Article
Closed access
ASAslıhan Sanrı
Aslıhan Sanrı
MMMehmet Burak Mutlu
Mehmet Burak Mutlu
Background: Double genetic diagnoses are increasingly identified with the advent of genome-wide sequencing techniques. While MECP2 mutations are associated with Rett syndrome and EPHB4 mutations with vascular malformation syndromes, their co-occurrence has not been previously described. Case Presentation: We describe an 8-year-and-2-month-old girl presenting with global developmental delay, autism spectrum disorder, and stereotypic behaviors, along with multiple well-demarcated cutaneous vascular lesions. Although she had no clinical seizures, electroencephalogram revealed epileptiform discharges. Physical examination showed dysmorphic features and vascular anomalies, including telangiectatic pink-to-red macular vascular lesions. Whole exome sequencing (WES) identified two de novo heterozygous pathogenic variants: a missense mutation in MECP2 (c.433C>T; p.Arg145Cys), a gene classically implicated in Rett syndrome, and a nonsense mutation in EPHB4 (c.1093C>T; p.Arg365Ter), which has been previously associated with capillary malformation-arteriovenous malformation syndrome type 2. The neurodevelopmental findings, while consistent with the broader spectrum of MECP2-related disorders, along with coexisting vascular anomalies, were best accounted for by a dual genetic diagnosis involving both MECP2 and EPHB4. Conclusion: This case underscores the diagnostic value of considering dual genetic diagnoses in patients with complex phenotypes and highlights the role of WES in uncovering multilocus variation, thereby expanding the known phenotypic spectrum associated with MECP2 and EPHB4 mutations.

24 April 2025 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
VGVeysel Gök
Veysel Gök
AOAlper Ozcan
Alper Ozcan
FMFatma Türkan Mutlu
Fatma Türkan Mutlu
EYEbru Yılmaz
Ebru Yılmaz
DGDeniz Kocak Göl
Deniz Kocak Göl
EUEkrem Unal
Ekrem Unal
Inherited platelet disorders (IPDs) are characterized by thrombocytopenia, platelet dysfunction, or both, leading to recurrent bleeding and diagnostic challenges. Advances in genetic testing have significantly improved early and accurate diagnoses. This study aimed to evaluate the clinical and genetic spectrum of IPDs, identify diagnostic challenges, and assess outcomes of therapeutic interventions. We conducted a retrospective cohort study of 50 IPD patients. We performed clinical evaluations, peripheral smear analyses, and genetic testing to identify causative variants. Correlation between platelet counts, bleeding severity, and the effectiveness of treatments, such as hematopoietic stem cell transplantation and thrombopoietin receptor agonists, was analyzed. A total of 54.5% of cases showed autosomal dominant inheritance. Diagnostic delays were common, with many patients initially misdiagnosed as having immune thrombocytopenic purpura (ITP). There was a moderate, negative, statistically significant correlation between platelet counts and bleeding severity. Peripheral smear findings, such as stomatocytosis and macrothrombocytopenia, provided critical diagnostic clues. We identified novel mutations in GP1BA, ITGB3, NBEAL2, WAS, and MPL genes, which expanded our understanding of IPDs. Different treatment modalities were used. Hematopoietic stem cell transplantation was performed in severe systemic cases, such as Wiskott–Aldrich syndrome. Sitosterolemia was treated with ezetimibe. Thrombopoietin receptor agonists reduced bleeding in some patients. Integrating genetic, clinical, and laboratory findings is essential in providing accurate diagnoses and management of IPDs. Early genetic diagnosis and personalized therapeutic strategies improve outcomes. Future research should focus on functional studies of novel mutations and refining treatment protocols to enhance care for this complex population.